Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Sanofi 2Q11

Generic competition hits Lovenox and Taxotere, Genzyme sales up 16%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi 2Q11

2Q Revenues: $12.0 billion (+1%)

2Q Earnings: $3.0 billion (-13%)

YTD Revenues: $23.2 billion (-1%)

YTD Earnings: $6.2 billion (-12%)

Note: All percentage-changes based on local currency

Comments: Pharmaceutical sales were $10.3 billion  (+2%). Excluding Genzyme’s $1.1 billion contribution, sales were down 4%, a result of generic competition for Lovenox (-35%) and Taxotere (-65%). Diabetes sales were up 12% driven by Lantus (+15%) and Apidra (+30%). Genzyme revenues were up 16% in 2Q: Cerezyme sales were up 58%, Myozyme sales were up 42%, Renvela sales were up 15%, and Synvisc sales were up 17%. Emerging Markets sales reached $3.6 billion or 30% of Group sales. Vaccines sales were $1.0 billion in the quarter (-6%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters